Company intelligence / Profile preview
Deciphera Pharmaceuticals
Waltham, Massachusetts, United Statesdeciphera.com ↗
- Ownership
- Public · DCPH
- Employees
- ~350
- Development stage
- Other
01
Overview
Deciphera has received FDA approval for ROMVIMZA™ (vimseltinib) for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Their MOTION Phase 3 study met its primary endpoint with an Objective Response Rate of 40% compared to 0% for placebo. They also have QINLOCK® approved for fourth-line GIST treatment in multiple countries.
- Therapeutic areas
- GastroenterologyOncologyImmunologyHematology
- Modalities
- Small moleculesKinase inhibitors
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on Deciphera Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deciphera Pharmaceuticals.